In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Carving REMS Out of Oncology? FDA, ASCO Plan Follow-Up Workshop

This article was originally published in RPM Report

Executive Summary

FDA and the oncology community will continue discussions about the role of REMS in cancer care. The agency is clearly taking pushback from providers seriously.
Advertisement

Related Content

FDAAA Impact Analysis (Year 7): The Era of the “Breakthrough” REMS
FDAAA Fading? REMS Use Continues To Decline As Drug Safety Law Matures
The Commercial Impact of REMS Relief: Nplate/Promacta Sales Spike After Risk Management Changes
Swing for the Fences: FDA's Top Cancer Drug Official Urges "Home Run" Trial Designs for Targeted Therapies
Swing for the Fences: FDA's Top Cancer Drug Official Urges "Home Run" Trial Designs for Targeted Therapies
The Rebirth of A Niche Product: Three Silver Linings on the ESA REMS
Living With REMS: The New Regulatory Model Meets Commercial Reality
Defining Cancer Drug Development Part II: A Discussion with FDA's Pazdur

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS080753

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel